Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Trans-Tranilast 是抗过敏剂,可用于过敏性鼻炎、支气管哮喘和特应性皮炎的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 198 | 现货 | ||
5 mg | ¥ 465 | 现货 | ||
10 mg | ¥ 735 | 现货 | ||
25 mg | ¥ 1,280 | 现货 | ||
50 mg | ¥ 1,990 | 现货 | ||
100 mg | ¥ 2,970 | 现货 | ||
200 mg | ¥ 4,280 | 现货 | ||
500 mg | ¥ 6,680 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 469 | 现货 |
产品描述 | Trans-Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. |
体内活性 | Protodioscin (5 and 10 mg/kg) significantly improves glucose intolerance and reduced the levels of serum UA, BUN, Cr, TC and TG. Protodioscin significantly reduces renal concentrations of IL-1β, IL-6 and TNF-α by inhibiting the activation of nuclear factor-κB, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase and extracellular signal-regulated kinase[1]. Protodioscin ameliorates the death rate, inhibits the increase in neurological deficit scores and infarct volume, and reduces the apoptotic nerve cells induced by MCAO in rats. Protodioscin attenuates the change of relevant apoptins, suppresses the release of pro-inflammatory cytokines in serum and reverses the protein expression of NF-κB (in nucleus and cytoplasm) and IκBα (in cytoplasm) induced by MCAO in rats[2]. Protodioscin (0.5?mg/kg, i.p.) increases the coagulation time by appr?50?% as compared to that of high-fat diet control rats. Protodioscin possesses a promising effect in lowering the blood levels of both lipoproteins, especially LDL, thus resulting in a high ratio of HDL/LDL[3]. |
别名 | Tranilast trans-, 反式-曲尼司特, 反-曲尼司特 |
分子量 | 327.33 |
分子式 | C18H17NO5 |
CAS No. | 70806-55-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL(183.3 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.055 mL | 15.2751 mL | 30.5502 mL | 76.3755 mL |
5 mM | 0.611 mL | 3.055 mL | 6.11 mL | 15.2751 mL | |
10 mM | 0.3055 mL | 1.5275 mL | 3.055 mL | 7.6376 mL | |
20 mM | 0.1528 mL | 0.7638 mL | 1.5275 mL | 3.8188 mL | |
50 mM | 0.0611 mL | 0.3055 mL | 0.611 mL | 1.5275 mL | |
100 mM | 0.0306 mL | 0.1528 mL | 0.3055 mL | 0.7638 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Trans-Tranilast 70806-55-2 Endocrinology/Hormones RAAS Trans Tranilast trans-SB 252218 Inhibitor Angiotensin Receptor TransTranilast Tranilast trans- trans-Tranilast 反式-曲尼司特 inhibit 反-曲尼司特 inhibitor